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AbstrAct
Introduction Tinnitus is the perception of sound in the 
absence of a corresponding external acoustic stimulus. 
Bimodal neuromodulation is emerging as a promising 
treatment for this condition. The main objectives of this 
study are to investigate the relevance of interstimulus 
timing and the choices of acoustic and tongue stimuli 
for a proprietary bimodal (auditory and somatosensory) 
neuromodulation device, as well as to explore whether 
specific subtypes of patients are differentially responsive 
to this novel intervention for reducing the symptoms of 
chronic tinnitus.
Methods and analysis This is a two-site, randomised, 
triple-blind, exploratory study of a proprietary 
neuromodulation device with a pre–post and 12-month 
follow-up design. Three different bimodal stimulation 
parameter sets will be examined. The study will enrol 342 
patients, split 80:20 between two sites (Dublin, Ireland 
and Regensburg, Germany), to complete 12 weeks of 
treatment with the device. Patients will be allocated to one 
of three arms using a stepwise stratification according 
to four binary categories: tinnitus tonality, sound level 
tolerance (using loudness discomfort level of <60 dB 
SL as an indicator for hyperacusis), hearing thresholds 
and presence of a noise-induced audiometric profile. 
The main indicators of relative clinical efficacy for the 
three different parameter sets are two patient-reported 
outcomes measures, the Tinnitus Handicap Inventory 
and the Tinnitus Functional Index, after 12 weeks of 
intervention. Clinical efficacy will be further explored in 
a series of patient subtypes, split by the stratification 
variables and by presence of a somatic tinnitus. Evidence 
for sustained effects on the psychological and functional 
impact of tinnitus will be followed up for 12 months. Safety 
data will be collected and reported. A number of feasibility 
measures to inform future trial design include: reasons 
for exclusion, completeness of data collection, attrition 
rates, patient’s adherence to the device usage as per 
manufacturer’s instructions and evaluation of alternative 
methods for estimating tinnitus impact and tinnitus 
loudness.
Ethics and dissemination This study protocol is 
approved by the Tallaght Hospital/St. James’s Hospital 
Joint Research Ethics Committee in Dublin, Ireland, and by 
the Ethics Committee of the University Clinic Regensburg, 
Germany. Findings will be disseminated to relevant 
research, clinical, health service and patient communities 
through publications in peer-reviewed and popular science 
journals and presentations at scientific and clinical 
conferences.
trial registration number The trial is registered on  
ClinicalTrials. gov (NCT02669069) Pre-results.
IntroductIon
Tinnitus is the perception of sound in the 
absence of a corresponding external acoustic 
stimulus. The condition is most commonly 
referred to as ‘ringing in the ears’ but symp-
toms can manifest as buzzing, hissing or 
sizzling. Tinnitus often coincides with hearing 
loss and it is commonly believed that hearing 
loss may be a contributory factor.1 While the 
exact mechanisms responsible for tinnitus are 
yet to be fully elucidated, it is believed that 
the reduction in peripheral auditory input, 
due to hearing loss, results in pathological 
behaviours that are misinterpreted as sound 
within the central auditory systems.2
Tinnitus has traditionally been treated by 
means of acoustic stimulation with limited 
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Protocol
strengths and limitations of this study
 ► The main strength of this study is that it is a large 
two-site, triple-blinded, randomised trial that will 
provide exploratory evidence of the relevance of 
stimulation parameters on the clinical efficacy of 
different bimodal stimulation parameters and will 
inform future trial design.
 ► The study comprehensively characterises patients 
for subtyping and this will refine candidature for the 
intervention.
 ► Among the limitations of this study are the variability 
in duration between screening and enrolment 
and the selection of the investigated stimulation 
parameters.
 ► The online recruitment process may inadvertently 
introduce participant selection bias.
group.bmj.com on November 15, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
2 D'Arcy S, et al. BMJ Open 2017;7:e018465. doi:10.1136/bmjopen-2017-018465
Open Access 
success.3 Systematic reviews highlight a lack of double-
blind, randomised, controlled studies or quality clinical 
evidence supporting the efficacy of acoustic stimulation 
in treating tinnitus.4 This has led researchers to inves-
tigate approaches to treating tinnitus that go beyond 
acoustic stimulation.
One approach that has been increasingly investigated in 
the last decade is invasive and non-invasive neuromodula-
tion of brain structures and networks involved in tinnitus 
generation.5 6 Neuromodulation is defined as the process 
of inhibition, stimulation, modification, regulation or 
alteration of electrical activity in the central, periph-
eral or autonomic nervous systems.7 It is the science of 
how electrical stimulation can modulate nervous system 
functionality for therapeutic benefit. Neuromodulation 
approaches of the central nervous system for the treat-
ment of tinnitus include repetitive transcranial magnetic 
stimulation, transcranial direct current stimulation 
and epidural stimulation of temporal, temporoparietal 
and frontal brain areas. All of these approaches have 
resulted in reduction of tinnitus handicap in a subgroup 
of patients.8–11 In addition, neuromodulation employing 
cranial nerve stimulation has been investigated for 
tinnitus treatment in humans12 13.
To date, a limited number of uncontrolled pilot studies 
have been conducted to assess the safety and initial effi-
cacy of neuromodulation employing cranial nerve stim-
ulation for tinnitus. These have included invasive vagus 
nerve stimulation (VNS),14 non-invasive stimulation of 
the vagus nerve15 16 and non-invasive cervico-trigeminal 
nerve stimulation (CTNS).12 13 While VNS demonstrated 
promising results in animals,17 human studies have 
demonstrated mixed results.14 16 18 Human studies using 
non-invasive CTNS have demonstrated promising initial 
efficacy.12 13 However, these results should be considered 
preliminary as the data stems from small pilot studies. 
The intervention evaluated by Hamilton and colleagues12 
used synchronised auditory and somatosensory stimula-
tion. However, recent animal research suggests that inter-
stimulus timing intervals may play an important part in 
the effectiveness of bimodal auditory and somatosensory 
stimulation on tinnitus.19 20 This theory is supported by 
the findings of a recent 20-patient human pilot study.13 
Similarly, there is debate in the literature about the choice 
of auditory stimuli and whether this should stimulate 
frequency channels associated with sensorineural hearing 
loss (CTNS approach)12 or frequency channels not asso-
ciated with hearing loss (VNS approach).14 Progression 
to randomised controlled trials (RCTs) with adequately 
powered sample size is needed. This study protocol 
represents the first important step towards that goal.
Hypothesis and aims
The main objectives of the study described here are to 
investigate the relevance of interstimulus timing and 
the choices of acoustic and tongue stimuli in order to 
optimise bimodal neuromodulation parameters for this 
treatment. Exploratory analyses will be conducted to 
investigate whether subtypes of patients are differentially 
responsive to this novel intervention. Safety data will also 
be collected and reported. Additional feasibility outcomes 
concern methodological and procedural uncertainties 
when this novel medical device is prescribed and fitted in 
a large sample of patients.
MEtHods And AnAlysIs
trial design
The Treatment Evaluation of Neuromodulation for 
Tinnitus (TENT-A) study is a two-site, randomised, 
triple-blind, exploratory study examining three different 
bimodal stimulation parameter sets. The treatment dura-
tion is 12 weeks and patients are followed up at 6 weeks, 6 
months and 12 months post-treatment cessation. TENT-A 
will be conducted at two sites: Wellcome Trust-HRB 
Clinical Research Facility, St. James’s Hospital, Dublin, 
Ireland and Tinnituszentrum Regensburg, University of 
Regensburg, Germany. The protocol was independently 
reviewed and approved by Research Ethics Committees 
of the Tallaght Hospital/St James’ Hospital (Ref: 2016–
03-List 11) and the University Clinic Regensburg (Ref: 
16-101-0186). The trial sponsor is Neuromod Devices 
Limited. The trial was registered on  ClinicalTrials. gov on 
27 January 2016 (Identifier: NCT02669069, Pre-results). 
The first patient was consented in 22 March 2016 with 
the last visit planned for May 2018. Our reporting follows 
standard protocol items for clinical trials defined in the 
SPIRIT 2013 Statement.21
Eligibility criteria
Eligible patients will be aged 18–70 years at screening; 
self-report having experienced tinnitus for >3 months and 
<5 years; score between 28 and 76 points on the Tinnitus 
Handicap Inventory (THI), have a Minimum Masking 
Level (MML) measurement between 20 and 80 deci-
bels hearing level (dB HL), be able to read and under-
stand English or German (depending on the recruiting 
centre) and be willing to commit to the duration of the 
programme.
Potential patients will be excluded if they have pulsatile 
tinnitus (rhythmical sounds that often beat in time with 
the heartbeat), tinnitus caused by head or neck injury, 
or tinnitus resulting from any other neurological condi-
tion. Signs of a conductive hearing loss demonstrated 
by abnormal otoscopy or tympanometry are exclusion 
criteria; as is a sensorineural hearing loss in either ear 
of >40 dB HL in at least one measurement frequency in 
the range 0.25–1.00 kHz, or of >80 dB HL in at least one 
measurement frequency in the range 2.0–8.0 kHz. Exclu-
sions also include those patients who began wearing a 
hearing aid within the last 90 days, those with any type 
of electro-active implantable device (eg, vagal nerve 
stimulator, cochlear implant or a cardiopacemaker) 
and those with the following conditions that can be 
comorbid with tinnitus: Ménière’s disease, loudness 
discomfort level for sounds presented <30 dB sensation 
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Table 1 Stimulation parameter set for the three parallel arms
Auditory stimulation
Temporal relationship with somatosensory 
stimulation
Arm 1 Sequence of tones mixed with a broadband noise that is 
spectrally modified to compensate for any hearing loss
Somatosensory pulses are synchronised with the tones
Arm 2 Sequence of tones mixed with a broadband noise that is 
spectrally modified to compensate for any hearing loss
Somatosensory pulses are temporally aligned with the 
tones with varying short delays
Arm 3 Sequence of tones mixed with a broadband noise with the 
spectral range outside the regions normally associated with 
sensorineural hearing loss
Somatosensory pulses are temporally aligned with the 
tones with varying long delays
level (SL), temporomandibular joint disorder (TMJ) 
and anxiety determined by a score >120 out of 160 on 
the state-trait anxiety inventory (STAI).22 23 Moderate 
to severe dementia as indicated by a score <20 on the 
mini-mental state examination (MMSE)24 will also be a 
sufficient reason for exclusion. A final set of exclusion 
criteria based on medical history taken at the screening 
assessment are: oral piercings, pregnancy, involvement in 
medicolegal cases, history of auditory hallucinations, any 
current neurological conditions that may lead to loss of 
consciousness (eg, epilepsy), current prescription of any 
drug for a central nervous system pathology and previous 
use of bimodal neuromodulation devices. Finally, the 
patient may be excluded if the principal investigator does 
not deem the candidate to be suitable for the study for 
other reasons not listed above.
Intervention
All enrolled patients will receive a proprietary bimodal 
auditory and somatosensory neuromodulation device 
(MBT, Neuromod Devices Ltd, Dublin, Ireland), which is 
a CE-marked Class IIa medical device. Auditory stimula-
tion is delivered through high-fidelity circumaural head-
phones and comprises a mixture of a wideband noise 
and sequences of pure tones. Stimulation of the somato-
sensory system is delivered electrically using an array 
of 32 transmucosal electrodes on the tongue. Somato-
sensory stimulation is delivered in the form of biphasic 
anodic-leading pulses of between 5 and 130 μs duration 
and fixed amplitude. The somatosensory stimulator is 
arranged so that there is a mapping between the elec-
trodes in the array and frequencies in the tone sequence. 
The stimuli for each parameter set across the three arms 
are outlined in table 1.
The auditory stimulus intensity is configured uniquely 
based on each patient’s pure-tone audiometric thresh-
olds in the range 0.25–8 kHz, and the patient is afforded 
limited control over the auditory stimulus intensity of 
−12 to +12 dB in 2 dB steps during treatment. For patients 
with >70 dB HL hearing loss at any frequency, the upper 
bound of stimulus intensity control is limited for reasons 
of safety noise dosage. The treatment device reverts to the 
default stimulus intensities at the start of each new treat-
ment session. Any adjustments made by the patients to 
the stimulus intensities are logged in the device’s memory 
for subsequent analysis.
The somatosensory stimulus intensity is configured for 
each patient at enrolment, based on a calibration proce-
dure that ascertains the patient’s threshold of percep-
tion. The patient is also afforded limited control over the 
somatosensory stimulus intensity during treatment.
The device logs the time and date on which the device 
is in use by the patient, the duration that the electrode 
array is in contact with the tongue and the intensities of 
both stimuli.
Individually configured devices will be delivered to the 
investigator sites with a patient’s unique identifier code 
(UIC) numbers marked on each device and its accesso-
ries. Investigators will be extensively trained on fitting the 
device and instructing patients on its use, per the manu-
facturer’s instructions. Patients will be provided with a 
quick start guide, an instructions for use (IFU) manual 
and a link to an instructional video. Before leaving the 
clinical sites, patients will complete a 30 minute super-
vised treatment session to ensure that they are comfort-
able using the device.
outcomes
Subjective clinical outcome measures to assess tinnitus 
impact are the Tinnitus Handicap Inventory (THI)25 and 
the Tinnitus Functional Index (TFI).26 The THI provides 
a measure of the psychological impact of tinnitus, in 
which 25 items are scored 4/2/0 on a categorical scale 
corresponding to yes/sometimes/no. The global score of 
the THI has a value between 0 and 100 with the higher 
scores indicating greater negative functional impact of 
tinnitus. The TFI assesses a range of functional complaints 
experienced over the past week.27 Each of the 25 items is 
assessed on an 11-point Likert scale, in which the sum of 
the scores is normalised to give a global score between 0 
and 100, with higher scores indicating greater negative 
functional impact of tinnitus.
Tinnitus loudness will be assessed by MML, tinnitus loud-
ness matching (TLM) and visual analogue scale (VAS). 
MML is a psychoacoustic estimate of the lowest level of 
broadband noise required to minimally mask the patient’s 
tinnitus.28 The stimulus is normally presented ipsilaterally 
(tinnitus ear), or if tinnitus is present in both ears, the 
stimulus is presented binaurally or to the ear with the 
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predominate sound. TLM will be assessed by presenting 
a 1 kHz tone29 contralateral to the predominant tinnitus 
ear or if tinnitus is equally loud in both sides or localised 
in the head, the stimuli will be presented to the ear with 
better hearing or randomly selected. The stimulus will be 
increased in 1 dB increments until the patient confirms 
that it is equal in loudness to their tinnitus. Finally, a VAS 
will be employed for patients to rate the current loudness 
of their tinnitus, with 0 equating to ‘not loud at all’ and 10 
equating to ‘extremely loud’, as the endpoints anchors.30
Safety data on adverse events (AEs) and serious adverse 
events (SAEs) will be captured throughout the trial. 
An AE is defined as any unfavourable and unintended 
sign, symptom or disease, temporarily that may or may 
not be related to the medical device. It will be rated as 
minor, major or serious and related or unrelated to the 
device by the TENT-A Medical Review Board. An SAE is 
defined as an AE that led or might have led to the death 
or serious deterioration in the state of health of a patient. 
Treatment-related AEs are those judged by the principal 
investigator at each site to be possibly caused by the treat-
ment under investigation. The principal investigator will 
remain vigilant for signs of possible treatment-related 
changes in oral health (eg, irritations in the oral cavity or 
discomfort between the tongue tip and dental retainers 
or metal fillings) and the impact of tinnitus (indicated by 
the THI and TFI).
Stopping criteria are defined as patients demonstrating 
a worsening in THI and MML of an increase in THI of 7 
points and an increase in MML of 5.3 dB. Treatment-re-
lated changes in hearing thresholds that are considered 
an AE are a deterioration from screening to endpoint 
of 15 dB in a minimum of two adjacent test frequencies 
(0.25–8 kHz) in either ear that cannot be explained by 
conductive hearing problem or a recent excessive noise 
exposure.
Additionally, feasibility outcomes include: reasons for 
exclusion at the screening visit, number of patients who 
were eligible at the screening appointment but declined 
to participate further, number of patient withdrawals 
after device fitting, proportion of incomplete patient 
datasets at each scheduled visit, patients’ compliance with 
the device usage as per manufacturer’s instructions and 
comparisons of alternative methods for measuring the 
impact of tinnitus and for estimating tinnitus loudness.
Compliance data will be extracted from log files saved 
on the device. For feasibility analysis, compliance rate will 
be expressed as a percentage of logged usage relative to 
(i) the expected compliance as per the intended use for 
the device (a total of 84 hours over the 12-week period), 
and to (ii) a predefined minimum acceptable compli-
ance threshold (defined as at least 3 hours average usage 
within a 1-week period, corresponding to a sum total of 
36 hours of treatment).
recruitment
Patients will be primarily recruited via media advertising 
and dedicated trial websites in both clinical locations. 
Advertisements on regional and national radio stations 
and in regional and national newspapers will invite indi-
viduals with tinnitus, who are interested in participating 
in a clinical study for tinnitus, to register their interest on 
dedicated recruitment websites. The recruitment website 
provides information on the study and how to proceed 
with registration. Once they register their interest, candi-
dates will be provided with a UIC and an accompanying 
personal identification number and be directed to an 
eligibility assessment website. The eligibility assessment 
comprises an online survey, hosted by SurveyGizmo, 
where those interested can find out about the require-
ments of participating in the study. Candidates will answer 
a scripted set of general prescreening questions on age, 
duration of tinnitus, oral piercings, other current medical 
conditions including TMJ disorder and Ménière’s disease 
and involvement in medicolegal cases. This is not part 
of the formal screening because no personal or medical 
details will be taken, but it is intended to manage the 
large numbers of candidates expected to respond to the 
advertising campaign and anticipated high screen failure 
rate. Candidates who meet the inclusion criteria at this 
stage will be provided with a patient information leaflet 
and informed consent via email or post and invited to a 
screening visit at the local site.
Patient timeline
The schedule of clinical research activities is illustrated 
in table 2 and briefly comprises seven visits to the clin-
ical site, plus two telephone calls during the period of 
device usage. The various assessments are completed by 
a multidisciplinary team including: audiologists, medical 
doctors, physiotherapist, research nurses and research 
associates.
The initial objective of the screening visit is to obtain 
written informed consent to determine whether the 
patient satisfies the remaining eligibility criteria and to 
obtain initial outcome measures, patient characteristics 
and audiological profile. This information is employed 
in the subtype classification of patients, the stratified 
random allocation process and for device configuration, 
described below.
At the enrolment and device fitting visit, a physio-
therapist (Dublin) or medical doctor (Regensburg) 
conducts a comprehensive assessment comprising a 
set of 25 predefined cranial manipulations designed to 
diagnose somatic tinnitus.31 We define somatic tinnitus 
where a patient reports that at least one of the somatic 
manipulations reliably produces a change in the psycho-
acoustic characteristics of their tinnitus (e.g., in pitch, 
loudness, localisation, temporal properties and so on). 
Assessments of outcome measures are repeated at the 
enrolment visit. Other elements of the visit include an 
oral health examination and device training and deploy-
ment. After completing an on-site supervised treatment 
session, patients return home and self-administer the 
treatment. Patients will be instructed to use the device 
for two daily 30 min sessions over a 12-week period. 
group.bmj.com on November 15, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 5D'Arcy S, et al. BMJ Open 2017;7:e018465. doi:10.1136/bmjopen-2017-018465
Open Access
Ta
b
le
 2
 
S
ch
ed
ul
e 
of
 a
ss
es
sm
en
t,
T
im
e 
p
o
in
t
S
cr
ee
ni
ng
E
nr
o
lm
en
t 
an
d
 fi
tt
in
g
P
o
st
al
lo
ca
ti
o
n
Fo
llo
w
-u
p
Fo
llo
w
-u
p
Fo
llo
w
-u
p
S
cr
ee
ni
ng
E
nr
o
lm
en
t
Te
le
p
ho
ne
 c
al
l
In
te
ri
m
 v
is
it
Te
le
p
ho
ne
 c
al
l
E
nd
p
o
in
t 
vi
si
t
t 
- 
10
w
ks
t 
=
 0
t 
+
 3
w
ks
t 
+
 6
w
ks
t 
+
 9
w
ks
t 
+
 1
2w
ks
t 
+
 1
8w
ks
t 
+
 3
8w
ks
t 
+
 6
4w
ks
E
nr
ol
m
en
t
 
 E
lig
ib
ili
ty
 s
cr
ee
n
X
 
 In
fo
rm
ed
 c
on
se
nt
X
 
 A
llo
ca
tio
n
X
 
 Tr
ai
ni
ng
 o
n 
d
ev
ic
e 
us
ag
e.
X
 
 R
ev
ie
w
 o
f d
ev
ic
e 
us
ag
e 
d
at
a 
lo
g 
w
ith
 p
ar
tic
ip
an
t.
X
 
 E
nc
ou
ra
ge
 p
at
ie
nt
 c
om
p
lia
nc
e.
X
X
X
X
 
 R
et
ur
n 
d
ev
ic
e.
X
In
te
rv
en
tio
ns
 
 A
rm
 1
X
X
X
X
X
 
 A
rm
 2
X
X
X
X
X
 
 A
rm
 3
X
X
X
X
X
A
ss
es
sm
en
ts
 
 M
ed
ic
al
 h
is
to
ry
X
 
 P
re
vi
ou
s 
or
 c
on
co
m
ita
nt
 m
ed
ic
at
io
ns
/il
ln
es
se
s
X
X
X
X
X
X
 
 Ti
nn
itu
s 
lo
ca
tio
n 
&
 t
on
al
ity
X
X
X
X
X
X
X
 
 A
ud
io
m
et
ric
 t
es
ts
 o
f h
ea
rin
g
X
X
 
 Lo
ud
ne
ss
 D
is
co
m
fo
rt
 L
ev
el
 (L
D
L)
X
X
 
 M
in
i-
M
en
ta
l S
ta
te
 E
xa
m
in
at
io
n 
(M
M
S
E
)
X
 
 S
om
at
ic
 a
ss
es
sm
en
t
X
 
 O
ra
l a
ss
es
sm
en
t
X
X
 
 R
eg
en
sb
ur
g 
In
so
m
ni
a 
S
ca
le
X
X
 
 S
ta
te
-T
ra
it 
A
nx
ie
ty
 In
ve
nt
or
y 
(S
TA
I)
X
X
X
 
 Ti
nn
itu
s 
Fu
nc
tio
na
l I
nd
ex
 (T
FI
)
X
X
X
X
X
X
 
 M
in
im
um
 M
as
ki
ng
 L
ev
el
 (M
M
L)
X
X
X
X
X
X
X
 
 Ti
nn
itu
s 
Lo
ud
ne
ss
 M
at
ch
in
g 
(T
LM
)
X
X
X
X
X
X
X
 
 Ti
nn
itu
s 
H
an
d
ic
ap
 In
ve
nt
or
y 
(T
H
I)
X
X
X
X
X
X
X
 
 V
is
ua
l A
na
lo
gu
e 
S
ca
le
 (V
A
S
) (
lo
ud
ne
ss
 a
nd
 
in
tr
us
iv
en
es
s)
X
X
X
X
X
 
 A
d
ve
rs
e 
ev
en
ts
X
X
X
X
X
X
 
 C
lin
ic
al
 G
lo
b
al
 Im
p
re
ss
io
n 
(C
G
I) 
(lo
ud
ne
ss
 a
nd
 
in
tr
us
iv
en
es
s)
X
X
X
X
X
 
 D
ev
ic
e 
us
ab
ili
ty
 q
ue
st
io
nn
ai
r e
X
 
 H
yp
er
ac
us
is
 q
ue
st
io
nn
ai
re
X
1
X
2
w
k,
 w
ee
k.
1 D
ub
lin
, 2
G
er
m
an
y.
group.bmj.com on November 15, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
6 D'Arcy S, et al. BMJ Open 2017;7:e018465. doi:10.1136/bmjopen-2017-018465
Open Access 
Figure 1 Anticipated flow of participants through the TENT-A study. TENT-A, Treatment Evaluation of Neuromodulation for 
Tinnitus.
These sessions can be continuous or at different times 
of the day.
Assessment of outcome measures and safety informa-
tion are collected at the interim visit, half way through 
the 12-week treatment. Compliance will also be assessed 
and reviewed at the interim visit. Investigators will review 
the device usage log. Patients with acceptable compli-
ance will be encouraged to continue and patients with 
poor compliance will be encouraged to improve. Compli-
ance phone calls will be conducted at weeks 3 and 9 to 
encourage patients to continue with device usage and 
address any technical issues that patients may be having.
The purpose of the endpoint visit is to repeat outcome 
measures assessments, the oral health examination, an 
exit interview and retrieve the device. Three follow-up 
visits will be conducted to assess the post-cessation effects 
of this intervention.
sample size
The study is powered for a between-arm clinically signif-
icant difference in the mean THI scores from baseline 
to endpoint, where the reported clinically significant 
change in THI is 7 points.32 The assumed sample SD is 
12.7 points, as elucidated from a previous study using 
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similar technology,12 resulting in an effect size of 0.55. 
The sample size calculations were performed using 
MATLAB 2016a, assuming a two-sided significance level 
of 0.016 (0.05 split equally between the three interarm 
pairwise t-tests), and power of 90%, resulting in a total of 
91 patients to be enrolled in each treatment arm, or 114 
patients per arm to account for an expected drop-out rate 
of 20%. In total, 342 patients will be required across the 
three arms of the study, split 80:20 between the Dublin 
and Regensburg sites, respectively.
Allocation
Eligible patients will be randomised, in equal propor-
tions, between the three parallel arms (see figure 1). 
Stratified randomisation will be performed to balance the 
influence of several baseline covariates in the post-hoc 
analyses. The stratification covariates are chosen based on 
the investigator’s research objectives, namely to elucidate 
relative treatment effects on patients with tinnitus with 
varying underlying characteristics. Allocation of patients 
will be stratified across the three intervention arms 
according to four binary categories applied in a stepwise 
manner: (i) tinnitus tonality, (ii) sound level tolerance 
(using loudness discomfort level of <60 dB SL as an indi-
cator for hyperacusis), (iii) ‘normoacoustic’ (defined as 
pure-tone thresholds of ≤20 dB HL in all audiometric test 
frequencies between 0.25 and 8 kHz in both ears) and (iv) 
presence of a noise-induced audiometric profile (defined 
as a dip in pure-tone hearing thresholds of 10 dB or more 
in any frequency in the 3 to 6 kHz range in either ear). 
These covariates are not mutually exclusive, so priority 
during stratified randomisation will be given to the least 
prevalent covariates based on candidate characteristics 
from the screening phase of the study.
The stratification and randomisation will be performed 
adaptively (Minimisation),33 whereby the probability of 
assignment to a treatment intervention changes as the 
imbalance within the relevant stratum increases. Dice 
rolls emulated in MATLAB’s Mersenne Twister algorithm 
(V.2016a) will be used with the randomisation seed set to 
the date each new block of patients is randomised.
data collection methods
All data will be collected electronically using a validated 
electronic case report form (eCRF) application. Patient 
data collected at all stages of the trial will be entered 
into the eCRF using UIC’s assigned to patients at recruit-
ment phase. All investigators and patients will be blinded 
to allocation arm and no allocation information will be 
contained in the eCRF. The data monitors will be able to 
remotely view the data in the eCRF to monitor safety data.
statistical methods
The main indicators of clinical efficacy for the three 
different parameter sets are two patient-reported 
outcomes (THI and TFI) after 12 weeks of intervention. 
Baseline outcome measures are computed as the average 
scores at the screening and enrolment visits. Clinical 
efficacy will be explored for a series of patient subtypes, 
split by the stratification variables, while evidence for 
sustained effects on the psychological and functional 
impact of tinnitus will be followed up for 12 months. Addi-
tional feasibility measures to inform future trial design 
include: reasons for exclusion, completeness of data 
collection, attrition rates and patients’ adherence to the 
device usage as per manufacturer’s instructions. These 
will be collated using descriptive statistics and reported as 
percentages. We will also evaluate the alternative methods 
for estimating tinnitus impact and tinnitus loudness, as 
far as possible using psychometric criteria defined by the 
COnsensus-based Standards for the selection of health 
Measurement INstruments completed in line (COSMIN) 
checklist.34
Efficacy analyses will focus on investigating (i) 
between-arm changes in the THI and TFI outcome 
measures from baseline to endpoint, and (ii) within-arm 
changes in THI and TFI outcome measures from base-
line to endpoint, for the full cohort and then sequen-
tially testing the subtypes described above using serial 
gatekeeping to control the family-wise error rate at the 
0.05 significance level. The between-arm analyses will be 
based on an intention-to-treat estimand and tested with 
multiple regression using baseline scores as a covariate. 
Missing data will be handled by using Markov chain 
Monte Carlo multiple imputation methods35 36. The 
within-arm analyses will be based on a per-protocol esti-
mand and tested with paired two-tailed t-tests. The use 
of per-protocol estimand will ensure that the changes in 
outcome measures within a particular treatment arm are 
reflective of real-use scenarios, that is, where the patients 
use the treatment as directed. The threshold for inclu-
sion in the per-protocol analysis is set at the predefined 
minimum acceptable compliance threshold previously 
described. Additional exploratory efficacy analyses shall 
be conducted in order to ascertain treatment effects from 
baseline to interim (i.e. 6 weeks of treatment), and to 
evaluate any sustained efficacy by analysing changes in 
efficacy outcome measures from endpoint to the three 
follow-up assessments (i.e. at 18, 36 and 60 weeks after 
device fitting).
Safety analyses will be performed by evaluating the 
incidence of adverse events, classified as treatment or 
non-treatment related, and further sub-classified as 
minor, major and serious. Adverse events will be recorded 
proactively by monitoring significant changes in THI, TFI, 
MML; hearing thresholds and oral health; and reactively 
by documenting any adverse events reported by patients 
during the study. All adverse events will be analysed for 
trends, and statistical tests for significant between-arm 
differences will be conducted.
Efficacy and safety data analysis will be conducted 
in compliance with the Consolidated Standards of 
Reporting Trials guidelines for RCTs37 using the SAS soft-
ware package.
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dissemination
Findings will be disseminated to relevant research, clinical, 
health service and patient communities through publica-
tions in peer-reviewed and popular science journals and 
presentations at scientific and clinical conferences.
dIscussIon
This paper outlines the protocol for a multisite, 
randomised, triple-blind, exploratory study designed 
to explore the effects of different bimodal stimulation 
parameter sets across a number of tinnitus subtypes in 
a range of tinnitus clinical subdomains. The results of 
this study will inform the design of future triple-blind 
randomised control trials. The main objective is to deter-
mine an optimised bimodal stimulation parameter set, 
but we will also explore which patient characteristics 
might best predict therapeutic benefit to this treatment. 
We anticipate that this could lead to improved targeted 
intervention options for people with chronic subjective 
tinnitus.
This study is timely for several reasons. First, completing 
this exploratory trial will be important in determining any 
feasibility challenges and will be used to estimate the time, 
resources and sample size required for future confirma-
tory trials. Second, findings from this study could poten-
tially inform the acceptability of bimodal stimulation in 
the wider population. There is a recognised need for 
evidenced therapeutic options that reduce or alleviate the 
symptoms of tinnitus instead of simply helping sufferers 
to manage the cognitive, emotional and behaviour 
impacts of their long-term condition.3 Third, low-quality 
clinical trial design and reporting has been identified as 
a major barrier to developing effective tinnitus therapies 
and standards of practice have been proposed.38–40 The 
study design and protocol description are in line with 
those recommendations.
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